BETTA PHARMACEUTICALS: Will strive for more new drug approvals in high-incidence tumor areas such as lung cancer and breast cancer
BETTA PHARMACEUTICALS stated on the interactive platform that the company has gradually achieved the market launch of 8 new drugs and has established a promising R&D pipeline, with more than 20 ongoing projects related to tumor diseases such as lung cancer and breast cancer, as well as ophthalmic diseases like wAMD. Currently, the company is concentrating resources and focusing on development to strive for more new drug launches in high-incidence tumor areas such as lung cancer and breast cancer. In the future, as the drug promotion strategy is implemented, the company's revenue will continue to improve, positively impacting financial indicators
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments